Research & Publications
Dr. Lin received the B.S. degree from Rensselaer Polytechnic Institute and the Ph.D. degree from Duke University, all in biomedical engineering. He is currently the Director for Clinical Research in North America for Visage Imaging and is stationed at Yale-New Haven Hospital where he oversees, coordinates, drives and directs research collaborations with high profile academic hospitals in North America to develop new solutions for diagnostic image analysis and guidance that improve clinical and operational outcomes while reducing cost of care. This includes activities in Artificial Intelligence (AI) and Machine Learning (ML) in the Radiology enterprise diagnostic imaging solutions space. Dr. Lin identifies opportunities for academic-industry research partnerships, and acts as the liaison between Visage Imaging researchers and clinical collaborators to translate ideas to prototype for clinical validation, with the goal of technology transfer to product. A highlight is Ming coordinated the clinical data curation and ground-truth annotation for building a fully automatic breast density AI classifier that provides an ACR BI-RADS Atlas 5th Edition breast density category to aid radiologists in the assessment of breast tissue composition from full field digital mammography and digital breast tomosynthesis systems and drove the clinical validation with Yale radiologists and Visage developers that led to transfer to product and regulatory approvals in 21 months. Notably, this was the first for a major PACS vendor to offer a self-developed, FDA-cleared AI algorithm natively into their PACS: Visage Breast Density, K201411, 510(k) clearance, January 2021, Health Canada Licensed, October 2020, Australian TGA approval, July 2020, CE Mark Cleared, May 2020.
Dr. Lin also is directly involved in research to develop better ways to treat patients with liver cancer using transcatheter arterial chemoembolization (TACE) and in this context, he is also the chief engineer and operations manager of the Yale Interventional Oncology Research Lab. Dr. Lin is the Principle Investigator (PI) on two NIH R01 grants to improve the diagnosis, treatment, and response assessment after transcatheter arterial chemoembolization for patients with liver cancer. Dr. Lin is the inventor of 3D quantification TACE therapy response tool (qEASL) and in collaboration with clinical partners, validated, and showed clinical relevance (ability to predict patient survival) that led to transfer to commercial product (FDA 510(k) cleared December 2016 - Multi-Modality Tumor Tracking (MMTT) application). Prior to Visage Imaging, Dr. Lin was the Philips research site manager and senior researcher stationed onsite at Yale where he managed the research portfolio and partnership Philips has with Yale.
Education & Training
- PhDDuke University (2008)
- BSRensselaer Polytechnic Institute (2001)